Clinical Trial Update: Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating whether exenatide can prevent an increase in endogenous glucose production when dapagliflozin increases glucosuria in type 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2023-07-24